IL18BP _ IL18BPa Antibody
- Known as:
- IL18BP _ IL18BPa Antibody
- Catalog number:
- 10357-MM02
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Smart Serology
- Gene target:
- IL18BP _ IL18BPa Antibody
Related genes to: IL18BP _ IL18BPa Antibody
- Gene:
- IL18BP NIH gene
- Name:
- interleukin 18 binding protein
- Previous symbol:
- -
- Synonyms:
- IL18BPa
- Chromosome:
- 11q13.4
- Locus Type:
- gene with protein product
- Date approved:
- 1999-05-21
- Date modifiied:
- 2016-10-05
Related products to: IL18BP _ IL18BPa Antibody
Related articles to: IL18BP _ IL18BPa Antibody
- Fulminant viral hepatitis (FVH) in children is a rare but often fatal form of acute liver failure occurring in the absence of preexisting liver disease. Its exceptional incidence during otherwise common viral infections, including hepatitis A virus (HAV), hepatitis B virus (HBV), and herpes simplex virus (HSV), supports a decisive role for host susceptibility. Recent advances in human immunogenetics delineate two major, mechanistically distinct pathways to pediatric FVH. The first reflects failure of immune regulation, culminating in excessive IFN-γ-driven inflammation and immune-mediated hepatocellular necrosis. Autosomal recessive IL-18BP and IL-10RB deficiencies exemplify this mechanism, in which disruption of key regulatory checkpoints permits uncontrolled activation of cytotoxic lymphocytes and macrophage-dependent immunopathology, particularly in the context of HAV infection. The second pathway involves impaired intrinsic antiviral defense, most prominently through neutralizing autoantibodies against type I interferons, which phenocopy genetic defects of IFN-I signaling and are strongly associated with HSV-triggered FVH; in this setting, inadequate early antiviral control enables unchecked hepatic replication with extensive cytopathic damage. Finally, syndromic hyperinflammatory disorders, including familial hemophagocytic lymphohistiocytosis and X-linked lymphoproliferative disease, broaden the spectrum of immune predisposition in which fulminant hepatitis may arise. Together, these discoveries redefine pediatric FVH as an immunopathological syndrome and provide a framework for targeted genetic and serologic diagnosis and for mechanism-based interventions aimed at improving survival. - Source: PubMed
Publication date: 2026/08/07
Bousfiha MohamedBen Sabbahia DalalJouanguy EmmanuelleCasanova Jean-LaurentEl Bakkouri JalilaBousfiha Ahmed AzizAmenzoui Naima - Interleukin-18 (IL-18) is a pleiotropic cytokine of the IL-1 family that has an important role in antitumour and antiviral immunity. Growing interest in its therapeutic potential has led researchers to explore strategies that harness IL-18 to modulate the tumour microenvironment. For example, engineered T cells are being armoured with IL-18 to enhance adoptive cell therapies and strengthen other immunotherapy approaches. As these strategies move towards clinical application, a key translational challenge is identifying the molecular mechanisms that influence treatment response and resistance, crucial for guiding trial design and patient selection across tumour types. This Review revisits the fundamental biology of IL-18, including its origins, cellular sources and regulatory networks, particularly those involving IL-18 binding protein (IL-18BP) and IL-37. We discuss how IL-18 promotes interferon-γ (IFNγ) production within the tumour microenvironment, supporting M1-like macrophage polarization, CD8 cytotoxic T cell and CD4 T helper 1 cell responses, natural killer cell activity and durable T cell memory. We also discuss preclinical models of IL-18 delivery, including dendritic cell platforms and cellular therapies, and highlight emerging strategies such as IL-18BP blockade and IL-18-secreting CAR T cells. Finally, we review results from early clinical studies and outline key challenges for translation, including the dual protumour and antitumour roles of IL-18. - Source: PubMed
Publication date: 2026/07/16
Sharma AkshatBishara Gina GOlejniczak Scott HOhm Joyce EBrentjens Renier JGupta Ajay - Immune checkpoint inhibitors have revolutionized cancer therapy, yet a substantial proportion of patients exhibit primary or acquired resistance. Immunocytokines offer a strategy to enhance antitumor immunity by delivering cytokine signals selectively to the tumor microenvironment. Here, we describe the immunoconjugate anti-programmed cell death protein 1 (PD-1)-interleukin (IL)-18 (aPD1-IL18), designed to couple PD-1-blockade with localized IL-18-mediated immune activation. - Source: PubMed
Publication date: 2026/07/14
Oelgarth NicoleMartin KeaJunker FabianSerger ClaraHerr CaoimheBuchi MélanieGremlich LilianFusi IreneFürst JonasHerzig PetraMoosmann PhilippHeinzelmann-Schwarz ViolaMertz Kirsten DRosenberg RobertSchaeuble KarinCarralot Jean-PhilippeLuu Thuy TKreft BertoltPattabiraman VijayaZippelius Alfred - This study aimed to develop and validate an adenosynergic prognostic signature for stratifying clinical outcomes and characterizing the tumor immune microenvironment in patients with EOC. - Source: PubMed
Publication date: 2026/06/29
Ibrahimo AkbarNovruzova Fidan - Nasopharyngeal carcinoma (NPC) is a multifactorial malignancy often diagnosed at an advanced stage due to nonspecific early symptoms. Accurate prognostic stratification is essential for individualized therapy but remains challenging because of biological and clinical heterogeneity. This study aimed to develop and validate a gene expression-based prognostic signature for locally advanced NPC. - Source: PubMed
Publication date: 2026/07/01
Li HuapingJing QiuyuChow James Chung HangCheuk WahChan Kenneth Sik KwanHao SuyuIslam Kazi AnishaDai WeiLam Ka OnLee Victor Ho FunNg Wai TongNgan Roger Kai CheongLee Anne Wing MuiWong Jason Wing HonChiang Chi Leung